Bio Rad Laboratories


SKU: MRNA-1 Category:


Bio Rad Laboratories: Initiation of Coverage – Unveiling the Future – Next-Gen Products That Will Skyrocket Your Portfolio! 


This is our first report on life science research and clinical diagnostic products manufacturer, Bio[1]Rad Laboratories. The company’s results exhibit resilience with substantial room for improvements and growth in the coming years. Bio-Rad’s FY 2023 net sales of $2.671 billion reflect a decrease by 4.7% on a reported basis as compared to 2022. Considering that COVID-related sales for that year were about $4 million compared to $109 million in 2022, the core year-over-year revenue remained effectively flat on a currency-neutral basis, demonstrating that the company has a solid fundamental performance outside of pandemic-related sales.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!